Comparative efficacy of Cimicifuga racemosa 1000cH and Rhododendron chrysanthum 1000cH in patients with trapezitis: a randomized comparative clinical study
Adolescência e Saúde · 03.11.2026 · 1619-1628
DOI: 10.67440/ahj.vi.3181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Adolescência e Saúde, online erschienen am 03.11.2026. Verfasst von Dr. Sumi T. S und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Trapezitis is a musculoskeletal condition characterized by pain, stiffness, and restricted movement, which can affect quality of life. Clinical evidence regarding the efficacy of Cimicifuga racemosa and Rhododendron chrysanthum in high dilutions in trapezitis is limited.
Aims
To compare the clinical outcomes of Cimicifuga racemosa 1000cH and Rhododendron chrysanthum 1000cH in patients aged 20–50 years with trapezitis. Methodology: In this randomized comparative clinical study, 52 participants aged 20–50 years were allocated to two groups of 26 participants each. Group A received Cimicifuga racemosa 1000cH and Group B received Rhododendron chrysanthum 1000cH. Pain intensity was assessed using the Visual Analogue Scale (VAS 0–10) before and after treatment. Symptom-wise improvement was recorded. Within-group changes were analysed using paired t-tests and between-group differences using unpaired t-tests.
Results
Mean VAS decreased from 7.62 ± 1.06 to 1.73 ± 1.64 in Group A and from 7.38 ± 1.10 to 3.62 ± 2.37 in Group B. Within-group reductions were statistically significant in both groups (p < 0.0001). The between-group difference was significant for post-treatment VAS (p = 0.0017) and mean VAS change (p = 0.0020). Mean VAS reduction was 77.68% in Group A and 49.08% in Group B. Symptom-wise improvement was recorded for pain in the neck, stiffness, headache, numbness and limitation of range of motion in both groups.
Conclusions
Both treatment groups showed improvement in VAS and recorded symptoms. In this study population, the reduction in VAS was greater with Cimicifuga racemosa 1000cH than with Rhododendron chrysanthum 1000cH. Interpretation is limited by the study design and requires confirmation in adequately registered, blinded, larger controlled trials.
Zitieren
APA
S, D. S. T., & Jadhavrao, D. N. V. (2026). Comparative efficacy of Cimicifuga racemosa 1000cH and Rhododendron chrysanthum 1000cH in patients with trapezitis: a randomized comparative clinical study. Adolescência e Saúde, 1619-1628. https://doi.org/10.67440/ahj.vi.3181
Vancouver
S DST, Jadhavrao DNV. Comparative efficacy of Cimicifuga racemosa 1000cH and Rhododendron chrysanthum 1000cH in patients with trapezitis: a randomized comparative clinical study. Adolescência e Saúde. 2026:1619-1628. doi:10.67440/ahj.vi.3181
BibTeX
@article{S2026,
author = {S, Dr. Sumi T. and Jadhavrao, Dr. Neha V},
title = {Comparative efficacy of Cimicifuga racemosa 1000cH and Rhododendron chrysanthum 1000cH in patients with trapezitis: a randomized comparative clinical study},
journal = {Adolescência e Saúde},
year = {2026},
pages = {1619--1628},
doi = {10.67440/ahj.vi.3181}
}
EUVIMED